Trials / Completed
CompletedNCT04934696
A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential
A Phase 1 Study to Characterize the Effects of BMS-986166 on the Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone in Healthy Female Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the potential for a drug-drug interaction (DDI) when BMS-986166 and hormonal oral contraceptives are co-administered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986166 | Specified dose on specified days |
| DRUG | Oral contraceptive | Specified dose on specified days |
Timeline
- Start date
- 2021-08-03
- Primary completion
- 2022-01-25
- Completion
- 2022-01-25
- First posted
- 2021-06-22
- Last updated
- 2022-03-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04934696. Inclusion in this directory is not an endorsement.